A recent study analyzed the long-term efficacy and safety profile of anti–tumor necrosis factor (anti-TNF) treatment in 15 patients with rhupus, a rare association defined by the coexistence of both systemic lupus erythematosus and rheumatoid arthritis (RA) in the same patient.
A study published in December 2017 analyzed the long-term efficacy and safety profile of anti—tumor necrosis factor (anti-TNF) treatment in 15 patients with rhupus, a rare association defined by the coexistence of both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in the same patient. Authors of the study note that, to date, there have been no previous studies regarding the use of anti-TNF agents in the treatment of rhupus.
Researchers conducted an open-label, single-center pilot study comprising 15 patients diagnosed with rhupus from 2003 to 2012 with a disease activity score for 28 joints (DAS28) over 3.2. Patients were monitored at 3, 6, 12, 24, and 60 months using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and DAS28.
Of the 15 patients included in the study, 12 were treated with etanercept for a median duration of 62.5 months, and 3 patients were given adalimumab for a median of 36 months. At baseline, median DAS28 and SLEDAI were 5.94 and 6, respectively, in the 2 groups. After 3 months of treatment, DAS28 and SLEDAI decreased to 3.7 and 4, respectively. The authors found that the tolerability and safety profile of the anti-TNF agents were acceptable, with a severe infection rate of 3 per 100 patient years, and with no lupus flares occurring during the follow-up.
The researchers concluded that anti-TNF treatment resulted in an improvement of articular symptoms with a significant decrease of DAS28 score. The SLEDAI score decreased after 3 months of therapy, and these numbers were sustained during the follow-up. Notably, this score also declined without taking into account the arthritis component of the SLEDAI, which the authors suggest could mean that anti-TNF agents could improve the non-articular features of lupus.
This small-scale study suggested that anti-TNF treatment has a “favorable efficacy, a decrease in the median dose of glucocorticoids, and an acceptable tolerance profile in patients with rhupus with refractive arthritis,” said the researchers.
Reference
Danion F, Sparsa L, Arnaud L, et al. Long-term efficacy and safety of anti-tumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. RMD Open. 2017;3:e000555. doi: 10.1136/rmdopen-2017-000555.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).